Relmada Therapeutics 将来の成長

Future 基準チェック /06

Relmada Therapeuticsの収益は年間2.9%で減少すると予測されていますが、年間収益は年間67.2%で増加すると予想されています。EPS は年間17.4%で増加すると予想されています。

主要情報

-2.9%

収益成長率

17.44%

EPS成長率

Pharmaceuticals 収益成長	10.9%
収益成長率	67.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	20 Mar 2026

今後の成長に関する最新情報

Recent updates

Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech

Mar 20Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsivity related neurological disorders. What are the underlying business or industry changes driving this perspective?

Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook

Mar 05Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsive behavior disorders such as Prader Willi syndrome. What are the underlying business or industry changes driving this perspective?

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Mar 21

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 13

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Jan 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Dec 04

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct 14

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Sep 14

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Aug 09

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Jul 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Feb 26

4 Clinical Catalysts On Tap For Relmada In 2022

Jan 28

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Nov 04

Our First Look At Relmada Therapeutics

Jun 28

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Jun 28

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 09

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Jan 15

業績と収益の成長予測

NasdaqCM:RLMD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	13	-122	-77	-106	3
12/31/2027	N/A	-104	-36	-87	4
12/31/2026	N/A	-83	-30	-81	4
12/31/2025	N/A	-57	-46	-46	N/A
9/30/2025	N/A	-56	-40	-40	N/A
6/30/2025	N/A	-68	-50	-50	N/A
3/31/2025	N/A	-76	-57	-57	N/A
12/31/2024	N/A	-80	-52	-52	N/A
9/30/2024	N/A	-86	-53	-53	N/A
6/30/2024	N/A	-87	-48	-48	N/A
3/31/2024	N/A	-94	-48	-48	N/A
12/31/2023	N/A	-99	-52	-52	N/A
9/30/2023	N/A	-112	-77	-77	N/A
6/30/2023	N/A	-129	-93	-93	N/A
3/31/2023	N/A	-144	-101	-101	N/A
12/31/2022	N/A	-157	-104	-104	N/A
9/30/2022	N/A	-153	-106	-106	N/A
6/30/2022	N/A	-157	-100	-100	N/A
3/31/2022	N/A	-143	-95	-95	N/A
12/31/2021	N/A	-126	-92	-92	N/A
9/30/2021	N/A	-112	-61	-61	N/A
6/30/2021	N/A	-86	-53	-53	N/A
3/31/2021	N/A	-71	-40	-40	N/A
12/31/2020	N/A	-59	-28	-28	N/A
9/30/2020	N/A	-43	-25	-25	N/A
6/30/2020	N/A	-30	-15	-15	N/A
3/31/2020	N/A	-23	-14	-14	N/A
12/31/2019	N/A	-15	-12	-12	N/A
9/30/2019	N/A	-18	N/A	-11	N/A
6/30/2019	N/A	-17	N/A	-10	N/A
3/31/2019	N/A	-17	N/A	-9	N/A
12/31/2018	N/A	-17	N/A	-9	N/A
9/30/2018	N/A	-11	N/A	-7	N/A
6/30/2018	N/A	-9	N/A	-6	N/A
3/31/2018	N/A	-7	N/A	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	N/A	-6	N/A	-5	N/A
6/30/2017	N/A	-6	N/A	-6	N/A
3/31/2017	N/A	-8	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-10	N/A
9/30/2016	N/A	-9	N/A	-12	N/A
6/30/2016	N/A	-3	N/A	-13	N/A
3/31/2016	N/A	6	N/A	-15	N/A
12/31/2015	N/A	6	N/A	-16	N/A
9/30/2015	N/A	14	N/A	-17	N/A
6/30/2015	N/A	-21	N/A	-16	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RLMD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RLMD今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RLMD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RLMD来年は収益がないと予測されています。

高い収益成長: RLMD来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RLMDの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/03/30 16:19
終値	2026/03/27 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Relmada Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。9

アナリスト	機関
Maxim Jacobs	Edison Investment Research
Farzin Haque	Jefferies LLC
Andrew Berens	Leerink Partners LLC

Relmada Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 93% to US$0.87

Price target increased by 18% to US$12.50

Price target increased by 13% to US$12.33

Price target increased by 24% to US$13.50

Price target increased by 30% to US$13.50

Price target increased by 24% to US$12.83

Recent updates

Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech

Relmada Therapeutics, Inc. announced that it has received $159.999996 million in funding from a group of investors

Relmada Therapeutics, Inc. to Report Q4, 2025 Results on Mar 19, 2026

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data For NDV-01 In Non-Muscle Invasive Bladder Cancer

Relmada Therapeutics, Inc. announced that it expects to receive $159.999996 million in funding from a group of investors

Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook

Relmada Therapeutics, Inc. Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Relmada Therapeutics, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Relmada Therapeutics, Inc. Announces Fda Feedback Supporting 2 Separate Acceptable Registrational Study Paths for Ndv-01 in Non-Muscle Invasive Bladder Cancer

Relmada Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000085 million.

Relmada Therapeutics, Inc. Appoints Distinguished Urologic Oncologist, Max Kates, Md, to the Clinical Advisory Board

Relmada Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025

The Nasdaq Stock Market Approves Relmada Therapeutics' Application to Transfer its Listing to the Nasdaq Capital Market

Relmada Therapeutics, Inc. Appoints Yair Lotan as to Chair of its Clinical Advisory Board

Relmada Therapeutics, Inc. Appoints Raj S. Pruthi as Chief Medical Officer-Urology

New major risk - Revenue and earnings growth

CEO & Director recently bought US$175k worth of stock

New major risk - Revenue and earnings growth

Relmada Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Relmada Therapeutics, Inc., Annual General Meeting, May 23, 2025

Relmada Therapeutics, Inc. to Report Q4, 2024 Results on Mar 27, 2025

New major risk - Market cap size

Relmada Therapeutics Receives Written Notification from Nasdaq Regarding Minimum Bid Price Requirement

Relmada Therapeutics, Inc. Elects Paul Kelly as Chief Operating Officer

Relmada Therapeutics to Discontinue the Reliance Ii and Relight Phase 3 Studies of Rel-1017

Price target decreased by 93% to US$0.87

Relmada Therapeutics, Inc. Announces Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Relmada Therapeutics, Inc. Initiates Phase 1 Dosing with Rel-P11 for Metabolic Disease

New major risk - Financial position

New major risk - Revenue and earnings growth

Relmada Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 18% to US$12.50

CEO & Director recently bought US$395k worth of stock

New major risk - Share price stability

New major risk - Revenue and earnings growth

Price target increased by 13% to US$12.33

Relmada Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Price target increased by 24% to US$13.50

Price target increased by 30% to US$13.50

Relmada Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Relmada Therapeutics, Inc., Annual General Meeting, May 24, 2024

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Relmada Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

New major risk - Share price stability

CEO & Director recently bought US$387k worth of stock

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Price target increased by 24% to US$12.83

Relmada Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder

Price target increased by 19% to US$12.67

New major risk - Revenue and earnings growth

Relmada Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Comp Value Index

Relmada Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors

Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

CEO & Director recently bought US$116k worth of stock

Price target decreased to US$17.42

High number of new and inexperienced directors

Price target decreased to US$17.42

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Price target increased to US$66.00